Rising Cancer Prevalence Globally Ignite the Demand for High Mobility Group Protein B1.

The global high mobility group protein B1 market is expected to grow at a significant CAGR during the forecast period (2022-2028). The rising prevalence of cancer such as leukemia and multiple myeloma, globally is a major factor driving market growth. As per the Leukemia & Lymphoma Society (LLS), total of 186,400 people in the US were diagnosed with leukemia, lymphoma or myeloma in 2021. 

Browse the full report description of “Global High Mobility Group Protein B1 Market Size, Share, and Trends, by Type (Dociparstat Sodium, RBM-005, EV-007156, and Others), by Application (Autoimmune Disorders, Chemotherapy Effects, and Others), and Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/high-mobility-group-protein-b1-market

Moreover, approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma and every 9 minutes, someone in the US dies from a blood cancer. In 2021, Leukemia, lymphoma and myeloma caused the deaths of an estimated 57,750 people in the US.  As a result, rising cancer rates are driving up demand for HMGB1. In cancer therapy, HMGB1 has been observed to regulate multiple signalling pathways, including proliferation, apoptosis, inflammation, immunity, autophagy, genome stability, metastasis, and metabolism, to promote both cell survival and death. 

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

? By Type

? By Application

• Regions Covered-

? North America

? Europe

? Asia-Pacific

? Rest of the World

• Competitive Landscape- Affibody AB, Cantex pharmaceuticals, Dicerna pharmaceuticals, and others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global High Mobility Group Protein B1 Market Report Segment

By Type 

• Dociparstat Sodium
• RBM-005
• EV-007156

By Application

• Autoimmune Disorders
• Chemotherapy Effects
• Cancer Treatment 

Global High Mobility Group Protein B1 Market Report Segment by Region

by Region

North America

• US

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/high-mobility-group-protein-b1-market